These findings indicate that IGF2BP3 promotes cell migration and invasion by activating EMT through HMGB1, and that glycyrrhizin has the potential to be used as a therapeutic option for bladder cancer treatment (Fig. 8E). The gene discussed is IGF2BP3; the disease is urinary bladder carcinoma.